|
1
|
Ward E, DeSantis C, Robbins A, Kohler B
and Jemal A: Childhood and adolescent cancer statistics, 2014. CA
Cancer J Clin. 64:83–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park JR, Bagatell R, London WB, Maris JM,
Cohn SL, Mattay KK and Hogarty M: COG Neuroblastoma Committee.
Children's Oncology Group's 2013 blueprint for research:
Neuroblastoma. Pediatr Blood Cancer. 60:985–993. 2013. View Article : Google Scholar
|
|
3
|
London WB, Bagatell R, Weigel BJ, Fox E,
Guo D, Van Ryn C, Naranjo A and Park JR: Historical time to disease
progression and progression-free survival in patients with
recurrent/refractory neuroblastoma treated in the modern era on
Children's Oncology Group early-phase trials. Cancer.
123:4914–4923. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
AACR Project GENIE: Powering precision
medicine through an international consortium. Cancer Discov.
7:818–831. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trigg RM and Turner SD: ALK in
neuroblastoma: Biological and therapeutic implications. Cancers
(Basel). 10:1132018. View Article : Google Scholar
|
|
6
|
Guan J, Fransson S, Siaw JT, Treis D, Van
den Eynden J, Chand D, Umapathy G, Ruuth K, Svenberg P, Wessman S,
et al: Clinical response of the novel activating ALK-I1171T
mutation in neuroblastoma to the ALK inhibitor ceritinib. Cold
Spring Harb Mol Case Stud. 4:a0025502018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wesche J, Haglund K and Haugsten EM:
Fibroblast growth factors and their receptors in cancer. Biochem J.
437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parker BC, Engels M, Annala M and Zhang W:
Emergence of FGFR family gene fusions as therapeutic targets in a
wide spectrum of solid tumours. J Pathol. 232:4–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vaughan L, Clarke PA, Barker K, Chanthery
Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, et
al: Inhibition of mTOR-kinase destabilizes MYCN and is a potential
therapy for MYCN-dependent tumors. Oncotarget. 7:57525–57544. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chesler L, Schlieve C, Goldenberg DD,
Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D and Weiss WA:
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn
protein and blocks malignant progression in neuroblastoma. Cancer
Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Segerström L, Baryawno N, Sveinbjörnsson
B, Wickström M, Elfman L, Kogner P and Johnsen JI: Effects of small
molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma
growth in vitro and in vivo. Int J Cancer. 129:2958–2965. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klempner SJ, Myers AP and Cantley LC: What
a tangled web we weave: Emerging resistance mechanisms to
inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov.
3:1345–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Nie J, Ma X, Wei Y, Peng Y and Wei
X: Targeting PI3K in cancer: Mechanisms and advances in clinical
trials. Mol Cancer. 18:262019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kostopoulou ON, Holzhauser S, Lange BKA,
Ohmayer A, Andonova T, Bersani C, Wickström M and Dalianis T:
Studies of FGFR3 and PIK3CA mutations in neuroblastomas and the
effects of the corresponding inhibitors in neuroblastoma cell
lines. Int J Oncol. 55:1372–1384. 2019.PubMed/NCBI
|
|
15
|
Biedler JL, Helson L and Spengler BA:
Morphology and growth, tumorigenicity, and cytogenetics of human
neuroblastoma cells in continuous culture. Cancer Res.
33:2643–2652. 1973.PubMed/NCBI
|
|
16
|
Biedler JL and Spengler BA: A novel
chromosome abnormality in human neuroblastoma and
antifolate-resistant Chines hamster cell lives in culture. J Natl
Cancer Inst. 57:683–695. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sugimoto T, Tatsumi E, Kemshead JT, Helson
L, Green AA and Minowada J: Determination of cell surface membrane
antigens common to both human neuroblastoma and leukemia-lymphoma
cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer
Inst. 73:51–57. 1984.PubMed/NCBI
|
|
18
|
Helson L and Helson C: Human neuroblastoma
cells and 13-cis-retinoic acid. Neurooncol. 3:39–41. 1985.
|
|
19
|
LaQuaglia MP, Kopp EB, Spengler BA, Meyers
MB and Biedler JL: Multidrug resistance in human neuroblastoma
cells. J Pediatr Surg. 26:1107–1112. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Holzhauser S, Lukoseviciute M, Andonova T,
Ursu RG, Dalianis T, Wickström M and Kostopoulou ON: Targeting
fibroblast growth factor receptor (FGFR) and phosphoinositide
3-kinase (PI3K) signaling pathways in medulloblastoma cell lines.
Anticancer Res. 40:53–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
André F, Ciruelos E, Rubovszky G, Campone
M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al:
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced
breast cancer. N Engl J Med. 380:1929–1940. 2019. View Article : Google Scholar
|
|
22
|
Bahleda R, Italiano A, Hierro C, Mita A,
Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, et al:
Multicenter phase I study of erdafitinib (JNJ-42756493), Oral
Pan-fibroblast growth factor receptor inhibitor, in patients with
advanced or refractory solid tumors. Clin Cancer Res. 25:4888–4897.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Foucquier J and Guedj M: Analysis of drug
combinations: Current methodological landscape. Pharmacol Res
Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Holzhauser S, Kostopoulou ON, Ohmayer A,
Lange BKA, Ramqvist T, Andonova T, Bersani C, Wickström M and
Dalianis T: In vitro antitumor effects of FGFR and PI3K inhibi-tors
on human papillomavirus positive and negative tonsillar and base of
tongue cancer cell lines. Oncol Lett. 18:6249–6260. 2019.PubMed/NCBI
|
|
26
|
Wang L, Šuštić T, Leite de Oliveira R,
Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den
Heuvel MM, Bernards R and van der Heijden MS: A functional genetic
screen identifies the phosphinositide 3-kinase pathway as a
determinant of resistance to fibroblast grown factor receptor
inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol.
71:858–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Mikse O, Liao RG, Li Y, Tan L,
Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated
ERBB2/3 activation confers acquired resistance to FGFR inhibition
in FGFR3-dependent cancer cells. Oncogene. 34:2167–2177. 2015.
View Article : Google Scholar
|
|
28
|
Herrera-Abreu MT, Pearson A, Campbell J,
Shnyder SD, Knowles MA, Ashworth A and Turner NC: Parallel RNA
interference screens identify EGFR activation as an escape
mechanism in FGFR3-mutant cancer. Cancer Discov. 3:1058–1071. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brands RC, Knierim LM, De Donno F,
Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter
UDA: Targeting VEGFR and FGFR in head and neck squamous cell
carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singleton KR, Hinz TK, Kleczko EK, Marek
LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi
screens reveal synergistic targeting of MTOR and FGFR1 pathways for
treatment of lung cancer and HNSCC. Cancer Res. 75:4398–4406. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai W, Song B and Ai H: Combined
inhibition of FGFR and mTOR pathways is effective in suppressing
ovarian cancer. Am J Transl Res. 11:1616–1625. 2019.PubMed/NCBI
|
|
32
|
Munster P, Aggarwal R, Hong D, Schellens
JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC,
Bergsland E, et al: First-in-Human phase I study of GSK2126458, an
Oral Pan-class I Phosphatidylinositol-3-Kinase inhibitor, in
patients with advanced solid tumor malignancies. Clin Cancer Res.
22:1932–1939. 2016. View Article : Google Scholar
|
|
33
|
Tamura R, Yoshihara K, Saito T, Ish imura
R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda
K, et al: Novel therapeutic strategy for cervical cancer harboring
FGFR3-TACC3 fusions. Oncogenesis. 7:42018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fulda S, Honer M, Menke-Moellers I and
Berthold F: Antiproliferative potential of cytostatic drugs on
neuroblastoma cells in vitro. Eur J Cancer. 31A:616–621. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng X, Naiditch J, Czurylo M, Jie C,
Lautz T, Clark S, Jafari N, Qiu Y, Chu F and Madonna MB:
Differential effect of long-term drug selection with doxorubicin
and vorinostat on neuroblastoma cells with cancer stem cell
characteristics. Cell Death Dis. 4:e7402013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Eschenburg G, Luckert C, Reinshagen K and
Bergholz R: Taurolidine cooperates with antineoplastic drugs in
neuroblastoma cells. Genes Cancer. 5:460–469. 2014. View Article : Google Scholar
|
|
37
|
Wickström M, Johnsen JI, Ponthan F,
Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson
K, Lewensohn R, Kogner P, et al: The novel melphalan prodrug J1
inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer
Ther. 6:2409–2417. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong CH, Ma BB, Cheong HT, Hui CW, Hui EP
and Chan AT: Preclinical evaluation of PI3K inhibitor BYL719 as a
single agent and its synergism in combination with cisplatin or MEK
inhibitor in nasopharyngeal carcinoma (NPC). Am J Cancer Res.
5:1496–1506. 2015.PubMed/NCBI
|
|
39
|
Keam B, Kim S, Ahn YO, Kim TM, Lee SH, Kim
DW and Heo DS: In vitro anticancer activity of PI3K alpha selective
inhibitor BYL719 in head and neck cancer. Anticancer Res.
35:175–182. 2015.PubMed/NCBI
|
|
40
|
Konstantinopoulos PA, Barry WT, Birrer M,
Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman
RL, Kochupurakkal B, et al: Olaparib and α-specific PI3K inhibitor
alpelisib for patients with epithelial ovarian cancer: A
dose-escalation and dose-expansion phase 1b trial. Lancet Oncol.
20:570–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
